Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of the next-generation of antibody-derived  drugs. The company uses proprietary technology to enable the development of singular molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into one protein (known as a Zybody). In addition, the technology will also be applied to drug targets that previously have not been reachable through the use of traditional, single specificity, monoclonal antibodies.

Zyngenia, which is headquartered in Montgomery County, Maryland - one of the nation's leading biotech hotbeds - intends to focus its early research and development in creating therapies for patients who have unmet medical needs in cancer and autoimmune diseases.